At ViGeneron, we’re experts in developing new gene therapy solutions.
While we’re focused on gene therapy to cure ophthalmic diseases, our next-generation gene therapy technology platforms also offer opportunities for use in other diseases such as those affecting the central nervous system, liver, or cardiovascular system.
The vgAAV vector platform, based on novel engineered AAV capsids, enables a superior transduction of target cells and is designed to efficiently cross biological barriers. These attributes enable intravitreal, less invasive gene delivery but also allows vgAAV vectors to target a broad spectrum of cell types in the retina and potentially in other tissues, such as the central nervous or the cardio-metabolic system.
In addition, our REVeRT vector platform utilizes a unique mRNA trans-splicing technology to develop safe and effective AAV gene therapy targeting large genes (>5Kb). REVeRT achieves high reconstitution efficiencies at the mRNA and protein level and is broadly applicable for various disease areas.
Our transactivation platform allows bi-directional modulation of multiple genes.
We are actively looking to work with leading biopharmaceutical companies or academics that wish to exploit these opportunities.
If you are interested in our technologies, please contact us: email@example.com
LMU is recognized as one of Europe's premier academic and research institutions. The research group of Professor Martin Biel at the Department of Pharmacy attracts scholars and talented students from all over the world. Outstanding scientists work there to develop new techniques for advanced gene therapies.
WuXi Advanced Therapies
The Advanced Therapies business unit of WuXi AppTec is dedicated to accelerating and transforming development, manufacturing, and commercialization of cell, gene, and other advanced biopharmaceuticals.
Regeneron (NASDAQ: REGN)
is a leading biotechnology company that invents life-transforming medicines for people with serious diseases.
Founded and led for nearly 35 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, nearly all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic diseases, infectious diseases and rare diseases. Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune®, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center®, which is conducting one of the largest genetics sequencing efforts in the world.